Pelthos Therapeutics Inc. (PTHS)

US — Healthcare Sector
Peers: CASI  LSTA  CLSD  KAPA  LEXX  PASG  LIXT  ENLV  MTVA  CING 

Automate Your Wheel Strategy on PTHS

With Tiblio's Option Bot, you can configure your own wheel strategy including PTHS - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

News

Pelthos Therapeutics Inc. (PTHS) Q3 2025 Earnings Call Transcript
PTHS
Published: November 13, 2025 by: Seeking Alpha
Sentiment: Neutral

Pelthos Therapeutics Inc. ( PTHS ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Mike Moyer Scott Plesha - CEO, President & Director Sai Rangarao Francis Knuettel - Chief Financial Officer Conference Call Participants Jeffrey Jones - Oppenheimer & Co. Inc., Research Division James Molloy - Alliance Global Partners, Research Division Presentation Operator Greetings, and welcome to the Pelthos Therapeutics Third Quarter 2025 Financial Results Conference Call. [Operator Instructions] Please note, this conference is being recorded.

Read More
image for news Pelthos Therapeutics Inc. (PTHS) Q3 2025 Earnings Call Transcript

About Pelthos Therapeutics Inc. (PTHS)

  • IPO Date 2025-07-02
  • Website https://pelthos.com
  • Industry Biotechnology
  • CEO Scott Plesha
  • Employees 4
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.